First Trust Advisors LP Reduces Stock Position in Teleflex Incorporated $TFX

Key Points

• First Trust Advisors LP cut its Teleflex stake by 98.4% in the first quarter, selling 161,067 shares and retaining 2,616 shares valued at about $313,000. Despite the sale, institutional investors collectively own 95.62% of the company.
• Analyst sentiment is mixed but improving: Royal Bank of Canada upgraded Teleflex to “outperform,” while the consensus rating remains “Hold” with an average price target of $151.80.
• Teleflex reported quarterly EPS of $1.76, beating estimates of $1.28, while revenue rose 28.9% year over year to $570.33 million. The company also declared a quarterly dividend of $0.34 per share, representing a 1.0% annualized yield.

First Trust Advisors LP cut its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 98.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,616 shares of the medical technology company's stock after selling 161,067 shares during the quarter. First Trust Advisors LP's holdings in Teleflex were worth $313,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC increased its stake in shares of Teleflex by 2.0% during the fourth quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company's stock valued at $518,196,000 after buying an additional 84,754 shares during the period. AQR Capital Management LLC raised its holdings in shares of Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock valued at $287,603,000 after acquiring an additional 1,956,811 shares in the last quarter. State Street Corp lifted its stake in Teleflex by 1.5% in the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company's stock worth $180,470,000 after acquiring an additional 22,111 shares during the period. Dimensional Fund Advisors LP lifted its stake in Teleflex by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company's stock worth $152,630,000 after acquiring an additional 5,051 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Teleflex by 10.6% in the fourth quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company's stock valued at $120,312,000 after acquiring an additional 94,679 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TFX. Raymond James Financial reissued an "outperform" rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday, May 8th. UBS Group raised their target price on shares of Teleflex from $145.00 to $158.00 and gave the stock a "neutral" rating in a research report on Tuesday. Royal Bank Of Canada raised shares of Teleflex from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $135.00 to $155.00 in a research note on Friday, May 8th. Wells Fargo & Company boosted their price target on shares of Teleflex from $130.00 to $138.00 and gave the company an "equal weight" rating in a research report on Friday, May 8th. Finally, BMO Capital Markets started coverage on shares of Teleflex in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $159.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $151.80.

Teleflex Stock Up 1.5%

NYSE:TFX opened at $135.55 on Thursday. The firm's 50-day moving average price is $132.13 and its 200-day moving average price is $123.34. The company has a market capitalization of $5.74 billion, a PE ratio of -5.82, a P/E/G ratio of 0.89 and a beta of 0.81. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12. Teleflex Incorporated has a 1-year low of $100.18 and a 1-year high of $145.00.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.48. The firm had revenue of $570.33 million for the quarter, compared to analysts' expectations of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The business's revenue for the quarter was up 28.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, equities analysts predict that Teleflex Incorporated will post 7.26 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex's dividend payout ratio is currently -5.84%.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source